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LETTERS TO THE EDITOR
The T-786C Endothelial
Nitric Oxide Synthase
Genotype and Coronary Artery Disease
We read with interest the article in JACC by Rossi et al. (1). These
investigators found that the C allele at the T-786C endothelial
nitric oxide synthase (ecNOS) polymorphism is associated with a
higher risk of coronary artery disease (CAD) in Caucasians,
especially in subjects older than 60 years of age. In their report, the
researchers affirm that there were no data supporting the relevance
of the T-786C polymorphism in non-Japanese populations. How-
ever, a previously published study by our group (2) concluded that
the NOS3-CC genotype would have a significantly increased risk
of suffering an early episode of CAD in Spanish subjects. The
study was based on 170 Spanish male patients (average age 42 
6 years) who had suffered an episode of CAD and had at least one
angiographically confirmed diseased vessel, and on 300 controls
younger than 60 years of age and without cardiovascular disease.
According to our results, the -786ecNOS-CC genotype confers an
increased risk of suffering an early episode of CAD, but additional
studies on other populations are required to confirm these results.
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REPLY
We appreciate the interest of Dr. Batalla and colleagues in the
recent study where we reported an association between multivessel
coronary artery disease (CAD), which was angiographically as-
sessed, and the -786C allele in the promoter region of the
endothelial nitric oxide synthase (eNOS) gene in Caucasians (1).
Consistent with our results, Batalla et al. claimed that the same
allele was previously reported to be associated with early CAD
(e.g., with an episode of CAD defined according to the guidelines
of the World Health Organization MONICA project) in male
smokers who were younger than 50 years (2). However, in our
view, the conclusions drawn in that study were not supported by
the results that were actually obtained, for several reasons.
First, although the reported C allele frequency (37% in controls
and 45% in CAD patients) was much higher than in Japanese
patients (3) and not far from that found in our report and in other
studies on Caucasians (1,4), the genotyping at this polymorphism
was carried out with the restriction fragment length polymorphism
(RFLP) analysis technique, a methodology that is far from
optimal. In a pilot study we compared this technique for T-786C
eNOS genotyping with the “gold standard” sequencing and found
inconsistent enzymatic cleavage that resulted in a substantial rate
of misgenotyped patients. Therefore, we abandoned RFLP and
replaced it with the more expensive melting curves analysis, which
provided accurate results as described in detail (5).
Second, by performing appropriate sample-size calculations
(nQuery version 5.0) on the results presented in the study that
Batalla et al. quoted (2), it is quite evident that that study was not
adequately powered to answer the questions that it posed (e.g., to
verify the hypothesis of an association between eNOS polymor-
phism and CAD). Given the reported sample sizes of 170 and 300
in the CAD patients and control groups, respectively (2), a
two-group 2 test with a 0.05 two-sided significance level has 54%
power to detect the difference of -786C allele frequency between
CAD patients (1 of 0.218) and controls (2 of 0.143) that was
observed (2). Therefore, in our view, the positive results mentioned
by Batalla et al. (2) were either luck or serendipitous findings.
Third, in the aforementioned study, the association between
CAD and eNOS -786C allele emerged as significant by compari-
son, with a 2 analysis, of the CAD patients and the controls, who
represented hospital staff, blood bank donors, and eligible resi-
dents. However, apart from the self-evident differences of sample
size between groups, it is altogether obvious from the results shown
that several differences were overlooked. Despite the fact that the
investigators carefully selected young male smokers as controls,
their groups differed markedly for total cholesterol (220  51
mg/dl vs. 119  42 mg/dl), HDL (high density lipoprotein)
cholesterol (32 8 mg/dl vs. 54 13 mg/dl), triglycerides (183
91 mg/dl vs. 120  72 mg/dl), and proportion of diabetic (10% vs.
0%) and hypertensive patients (31% vs. 0%). All differences were
highly significant (p  0.0001) from a statistical standpoint.
Therefore, compelling evidence existed for an unbalanced distri-
bution between CAD patients and controls of at least five
universally accepted cardiovascular risk factors. We also found a
similar unbalanced distribution of these and additional risk factors
in our study. Accordingly, we used a logistic regression analysis to
account for their confounding effects on the association of -786C
allele with CAD. In contrast, no such analysis was performed in
the study that Batalla et al. quoted (2).
Thus, in addition to the several limitations that were correctly
acknowledged by the investigators themselves (2) other serious
issues concerning the methodology used for genotyping, the power
of the study, and the way that results were analyzed precluded
drawing any conclusion concerning the association of the -786C
allele with CAD in the aforementioned study (2).
We carefully avoided any statements of primacy in our report
(1); however, it is quite evident at this time that our study was the
first to support with sound scientific data the relevance of the -786C
allele as a determinant of multivessel CAD in Caucasian patients.
Finally, we certainly agree with the conclusion by Dr. Batalla
and colleagues that further studies are necessary in this field.
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However, the fact that in another study we showed the functional
relevance of the same -786C allele in non-Japanese hypertensive
patients lends further support to the relevance of this polymor-
phism for cardiovascular disease in Caucasians (5).
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Response to Renin-Angiotensin System
Antagonists in Hypertensive Black Subjects
We read with interest the study by Flack et al. (1) which appeared
in the April 2, 2003, issue of the Journal. We commend the
researchers on investigating the effects of aldosterone antagonism
in the black population, who are traditionally underrepresented in
clinical trials. However, we have some concerns regarding the
characteristics of the study subjects.
First of all, we question the investigators’ use of weight, rather
than body mass index (BMI), as an anthropometric measurement.
Data from the Framingham Heart Study indicate that higher BMI
is a major determinant of inadequate blood pressure control with
antihypertensive medications (2). Though not statistically differ-
ent, both male and female subjects in the eplerenone group had
greater body weight than did those in the losartan group. Thus, we
are curious as to whether BMI differed between treatment groups
and, if so, whether these differences may have contributed to the
disparity in results between groups.
Second, the study included participants from both the U.S. and
Africa. The investigators do not report the percentage of black
participants who were from Africa versus those from the U.S. This
information is important in conferring the applicability of the
study findings to blacks in the U.S. Differences in environmental
factors have been reported among populations of African origin,
with higher BMI and greater sodium intake reported among
American blacks compared to African blacks (3). Similar to BMI,
sodium intake is a well-known factor influencing antihypertensive
response to renin-angiotensin system antagonists (4–6). Thus,
whether aldosterone antagonism would produce similar antihyper-
tensive effects in black Americans compared to black Africans is
uncertain.
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REPLY
We appreciate the questions raised by Humma and Adenekan
regarding the potential impact of body mass index (BMI) on the
blood pressure (BP)-lowering differences between eplerenone and
losartan in our recently published study. Also, the relevance of the
BP-lowering obtained in South African blacks to U.S. blacks was
raised.
There were 335 black participants in our trial; 260 (77.6%)
resided in the U.S. and 75 (22.4%) in South Africa. Black
participants were approximately evenly dispersed across treatment
groups with randomization to placebo, eplerenone, and losartan in
the following numbers (U.S. blacks/South African blacks): 1)
placebo (86/24); 2) eplerenone (83/25); and 3) losartan (91/26).
Blood pressure responses (SBP/DBP mm Hg) at 16 weeks (end of
trial) for blacks were: 1) placebo (3.7/4.8); 2) eplerenone
(13.5/10.2); and 3) losartan (5.3/6.0). Among South
African blacks, BP changes were: 1) placebo (1.1/4.1); 2)
eplerenone (11.6/10.1); and 3) losartan (0.8/3.6). The
overall rank-order of BP response was the same among U.S. and
South African blacks, although the absolute magnitude of change
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